Showing results (1091-1100 of 5,269) with videos related to

Sort By:
Pageof 527
European Journal of Haematology|June 17, 2014
Paroxysmal nocturnal hemoglobinuria with copy number-neutral 6pLOH in GPI (+) but not in GPI (-) granulocytesYasutaka Ueda, Jun-ichi Nishimura, Yoshiko Murakami, et al.
European Journal of Haematology|March 1, 1989
Cyclosporin-A therapy of pure red cell aplasia in a patient with B-cell chronic lymphocytic leukemiaR Christen, R Morant, J Fehr
European Journal of Haematology|June 4, 2014
Senescence of bone marrow mesenchymal stromal cells is accompanied by activation of p53/p21 pathway in myelodysplastic syndromesChengming Fei, Youshan Zhao, Juan Guo, et al.
European Journal of Haematology|June 4, 2014
Pregnancy in beta-thalassemia intermedia: 20-year experience of a Greek thalassemia centerErsi Voskaridou, Angeliki Balassopoulou, Effrossyni Boutou, et al.
European Journal of Haematology|June 4, 2014
The MDM2 polymorphism SNP309 is associated with clinical characteristics and outcome in diffuse large B-cell lymphomaGustav Hedström, Ulf Thunberg, Rose-Marie Amini, et al.
European Journal of Haematology|June 4, 2014
Mutations and thrombosis in essential thrombocythemia: prognostic interaction with age and thrombosis historyNaseema Gangat, Emnet A Wassie, Terra L Lasho, et al.
European Journal of Haematology|July 2, 2014
The clinical utility of Multiplate analyser measurement in platelet function testing following stroke and transient ischaemic attackGurdeep S Mannu, Alistair Macartney, Jonathan R A Lambert, et al.
European Journal of Haematology|January 23, 2015
Genetic susceptibility to diffuse large B-cell lymphoma in a pooled study of three Eastern Asian populationsBryan A Bassig, James R Cerhan, Wing-Yan Au, et al.
European Journal of Haematology|January 22, 2015
The kinetics of relapse in DEK-NUP214-positive acute myeloid leukemia patientsHans B Ommen, Aurore Touzart, Elisabeth MacIntyre, et al.
European Journal of Haematology|August 14, 2012
High serum vascular endothelial growth factor level is an adverse prognostic factor for high-risk diffuse large B-cell lymphoma patients treated with dose-dense chemoimmunotherapySari Riihijärvi, Heidi Nurmi, Harald Holte, et al.
Pageof 527